A(z) Biopharma csatorna legjobb podcastjai (2025)

1
Navigating The Complexity of Conditionally Active Biologics With Bonum Therapeutics' Diane Hollenbaugh, Ph.D., and Neela Patel, Ph.D. 47:49

2d ago47:49

47:49

In this episode of "Better Biopharma," host Tyler Menichiello is joined by Bonum Therapeutics' chief scientific officer, Diane Hollenbaugh, Ph.D., and chief business officer, Neela Patel, Ph.D. They talk about the inherent challenges of developing complex molecules like conditionally active biologics, sharing advice on CMC strategy, analytical meth…

1
Preview: Bo Wiinberg on Bridging Research and Trials with Cell-Based Therapies 22:24

24d ago22:24

22:24

Are cell therapies the key to bridging the gap between discovery research and clinical trials? In the inaugural episode of the Bioprocessing Unfiltered podcast, Bo Wiinberg, chief business development officer at Novo Nordisk Foundation Cellerator, sat with Ran Zheng, CEO of Landmark Bio and shared his expert insight on the promise cell therapies ho…

1
Developing Antibodies To Block Neuroinflammation With MindImmune's Stevin Zorn, Ph.D. 44:28

16d ago44:28

44:28

In this episode of "Better Biopharma," host Tyler Menichiello is joined by MindImmune's president and CEO, Stevin Zorn, Ph.D. They discuss the development of the company's lead candidate, MITI-101, a monoclonal antibody designed to prevent peripheral immune cells from entering the brain and driving neuroinflammation linked to Alzheimer's disease. F…

1
Engineering Bacterial Vector-Based Immunotherapies With OS Therapies’ Paul Romness and Robert Petit, Ph.D. 36:38

1M ago36:38

36:38

Tyler Menichiello által

1
How J&J Is Tackling Alzheimer's Disease With Fiona Elwood, Ph.D. 32:50

1M ago32:50

32:50

In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Fiona Elwood, Ph.D., VP and Neurodegeneration Disease Area Stronghold Leader at Johnson & Johnson. The two talk about J&J’s end-to-end organizational structure and its modality-agnostic approach to treating Alzheimer’s disease. Follow Tyler Menichiello on LinkedIn: https://w…

1
MindMed: Rethinking brain health with psychedelic therapy 11:58

2M ago11:58

11:58

Over the last 18 months, MindMed has undergone an extraordinary transformation. It released compelling data for its LSD-based drug MM120, followed by FDA breakthrough designation for MM120 for the treatment of GAD, and strong financial backing. CEO Rob Barrow outlines the company's ambitious goals and the path to potentially transforming mental hea…

1
CDMO Hunger Games And The State Of Biotech With Siren Biotechnology's Nicole Paulk, Ph.D. 1:00:40

2M ago1:00:40

1:00:40

In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Nicole Paulk, Ph.D., CEO and founder of Siren Biotechnology, a company developing a universal AAV immuno-gene therapy for cancer. They discuss the company’s decision to switch from plasmids to producer cell lines (PCLs) in production, the current funding environment for cell…

1
Funding the future of retinal health with Eyepoint 12:13

2M ago12:13

12:13

Eyepoint CFO George Elston provides insights on the evolving space of retinal disease treatment, focusing on capital allocation, medical innovation, industry engagement and financial prudence.

1
Delivering Biologics To The Brain With Adaptin Bio's Michael Roberts, Ph.D., and Duke University's Mustafa Khasraw, MD 36:11

2M ago36:11

36:11

In this episode of "Better Biopharma," host Tyler Menichiello is joined by Adaptin Bio's CEO, co-founder, and president, Michael Roberts, Ph.D., and Duke University's Mustafa Khasraw, MD. They discuss Adaptin's Brain Bispecific T-cell Engager (BRiTE) platform, its clinical potential to deliver therapeutic T cells across the blood-brain barrier, and…

1
Developing An In Vivo CAR-T With Interius BioTherapeutics' Sianny Christanti and Babu Medi, Ph.D. 48:39

3M ago48:39

48:39

On this episode of Better Biopharma, Interius BioTherapeutics’ Sianny Christanti and Babu Medi, Ph.D., explain how the company is re-engineering a lentiviral vector to enable INT2104, its off-the-shelf, in vivo CAR T-cell therapy. They discuss the vector's design and its manufacturability, as well as the analytical and regulatory challenges of brin…

1
Functional Antibody Screening With Abalone Bio's Richard Yu, Ph.D. 43:45

3M ago43:45

43:45

In this episode of Better Biopharma, Abalone Bio's CEO and co-founder, Richard Yu, Ph.D., explains how the company's functional antibody selection technology (FAST) platform differs from traditional affinity screening. Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/ Keep up with everything biomanufacturing at Bioproc…

1
How Blackstone Life Sciences is bridging the innovation gap 20:59

4M ago20:59

20:59

Paris Panayiotopoulos, Senior Managing Director at Blackstone Life Sciences, shares how the firm’s broad life sciences strategy has been advancing innovation across the life sciences ecosystem in three key ways: late-stage product financing (Collaboration) and new company creation (Ownership), and non-dilutive financing (Credit and Royalties). He e…

1
Compass trials mark a milestone moment for the psychedelics sector 12:35

4M ago12:35

12:35

Compass Pathways CEO Kabir Nath believes psilocybin-based therapy could be transformational for patients with treatment-resistant depression—and his company is already preparing to deliver it at scale. Speaking at RBC Capital Markets’ Global Healthcare Conference, Nath shares his vision for Compass and the future of psilocybin therapy for treatment…

1
Using Algae To Manufacture Oral Biologics With Lumen Bioscience's Craig Behnke, Ph.D. 44:34

4M ago44:34

44:34

Lumen Bioscience is putting the farm in biopharma — literally! In this episode of Better Biopharma, Lumen's EVP of production and development, Craig Behnke, Ph.D., explains the company's chlorophyll-powered approach to bioprocessing using photosynthetic cyanobacteria. Check out Behnke's past appearance on Business Of Biotech: https: //www.lifescien…

1
PILOT: Introducing Better Biopharma 2:45

4M ago2:45

2:45

How can the biopharmaceutical industry improve? Join Bioprocess Online's Tyler Menichiello as he explores this question through a series of interviews with experts and leaders from across the space. Subscribe for biweekly, in-depth conversations with the brightest minds in biotech to learn how they're moving the needle to make better medicines and …

1
Cidara’s pursuit of universal flu protection with a single dose 12:11

4M ago12:11

12:11

Every year, flu vaccine manufacturers have to guess what strains to target next season, with varying success. Cidara Therapeutics believes it may have a better alternative. President and CEO Jeff Stein explains how Cidara's laser-like focus on developing CD388, a single-dose antiviral targeting all flu strains, has brought the 40-person company on …

1
Market Access Success in Small Biotech | Ray Frost | Ep. 9 44:48

4M ago44:48

44:48

Market Access Success in Small Biotech | Ray Frost | Ep. 9 Ray Frost shares 20 years of market access expertise, revealing how small biotechs can successfully launch drugs in today's complex US healthcare landscape. In this episode of BioPharma Unscripted with Marcus Metcalfe, market access veteran Ray Frost discusses building commercial infrastruc…

1
Ocular Therapeutix’ bold vision to redefine retinal disease treatment 24:52

4M ago24:52

24:52

Pravin Dugel, CEO of Ocular Therapeutix provides insights into existing treatments and future product candidates for retinal diseases, underlining the unique challenges, opportunities and innovations in this evolving landscape. www.ocutx.com Pravin U. Dugel, MD BiographyRBC Capital Markets által

1
PTC Therapeutics: Building a durable company to benefit patients 14:01

4M ago14:01

14:01

A surgeon in burns reconstruction, Matt Klein swapped the operating room for the equally high-pressure environment of drug development. In this episode of Pathfinders in Biopharma, he sets out the vision for the company he now leads, PTC Therapeutics – a pioneer in the field of RNA therapies, now powering towards profitability with treatment candid…

1
From Forests to Pharma: Rasmus Jensen on Cultural Intelligence and Career Transformation - Ep. 8 51:57

5M ago51:57

51:57

From Forests to Pharma: Rasmus Jensen on Cultural Intelligence and Career Transformation - Ep. 8 Join Marcus Metcalfe as he sits down with Rasmus Jensen for a captivating conversation about one of the most unconventional career journeys in pharma. Starting with ambitions to become a forest ranger, complete with chainsaw training. Rasmus shares how …

1
BioAge is translating insights from the science of aging into new medicines 19:32

5M ago19:32

19:32

Scott Neidhold, Director in RBC’s Life Sciences Investment Banking Practice, sits down with Kristen Fortney, CEO and Co-Founder of BioAge, for a deep dive into how her company is turning cutting-edge aging science into real therapeutic breakthroughs — and what it means for the future of biopharma.RBC Capital Markets által

1
Value-Based Healthcare: Lessons from a HEOR Expert | BioPharma Unscripted! Ep.7 36:45

7M ago36:45

36:45

Value-Based Healthcare: Lessons from a HEOR Expert | BioPharma Unscripted! Ep.7 Join Marcus Metcalfe as he speaks with Colette Mankowski, a veteran in Health Economics, Outcomes Research & Market Access with over 25 years of industry experience. In this candid conversation, Colette shares her unconventional journey into health economics, her career…

1
Building Successful Market Access Strategies from Day One - BioPharma Unscripted Ep. 6 31:11

7M ago31:11

31:11

Building Successful Market Access Strategies from Day One - BioPharma Unscripted Ep. 6 In this episode of BioPharma Unscripted!, host Marcus speaks with pharmaceutical market access expert Ana Filipa Alexandre, PharmD, MPH about the critical importance of early access planning in drug development. Ana shares insights from her extensive career spann…

1
Regulatory Expertise for Early-Stage Biotechs | BioPharma Unscripted! Ep.5 19:25

7M ago19:25

19:25

Regulatory Expertise for Early-Stage Biotechs | BioPharma Unscripted! Ep.5 Join Marcus Metcalfe in conversation with Ming Ewe as they explore the critical role of regulatory expertise in early-stage biotech companies and advanced therapy development. In this insightful discussion, Ming shares her extensive experience as a regulatory mentor for biot…

1
Performance Communications in a Digital World | BioPharma Unscripted! Ep.4 36:31

8M ago36:31

36:31

Performance Communications in a Digital World | BioPharma Unscripted! Ep.4 Join Marcus Metcalfe in conversation with Jens Christmann as they explore the evolving world of corporate communications and digital transformation in the life sciences sector. In this engaging discussion, Jens shares insights from his journey transitioning from the FMCG wor…

1
Navigating the Freelance Path in Life Sciences | BioPharma Unscripted! Ep.3 17:15

8M ago17:15

17:15

Navigating the Freelance Path in Life Sciences | BioPharma Unscripted! Ep.3 Join Marcus Metcalfe in conversation with Hannah Kurth as they explore the rewarding yet challenging world of freelance consulting in the life sciences sector. In this candid discussion, Hannah shares her journey into freelance consulting after over two decades of experienc…

1
Uncertainty reigns, but opportunity persists for biotech’s 2025 9:17

9M ago9:17

9:17

Universal wisdom had it that a Republican sweep in the U.S. election would favor biotech. Appointments to the new administration’s healthcare leadership make that far less certain. What effect will this and other factors have on the industry in 2025, and where are the breakthroughs likely to be found? Brian Abrahams, Head of Global Healthcare Resea…

1
The Power of Interim Talent: Strategic Healthcare Expertise | BioPharma Unscripted! Ep.2 12:28

9M ago12:28

12:28

The Power of Interim Talent: Strategic Healthcare Expertise | BioPharma Unscripted! Ep.2 Join Marcus Metcalfe as he speaks with Andrew Xia about using interim consultants in the life sciences sector. In this insightful conversation, Andrew shares his perspective as an experienced interim consultant specialising in health economics, market access, a…

1
European Market Access Strategy: Navigate the Joint Clinical Assessment | BioPharma Unscripted! Ep.1 19:28

10M ago19:28

19:28

European Market Access Strategy: Navigating the Joint Clinical Assessment | Elucid8 Podcast Ep.1 Join Marcus Metcalfe speaking with Martin Gisby about European market access and the upcoming Joint Clinical Assessment (JCA) launching January 2025. Martin explains successful market access strategies in Europe, emphasising demonstrating comparative ef…

1
Unlocking Biotech’s Potential: Strategies for Navigating Public and Private Market Investments 22:38

12M ago22:38

22:38

Innovation is surging in the U.S biotechnology sector, so why are investors still fearful about committing? Noël Brown, Head of U.S. Biotechnology Investment Banking at RBC Capital Markets, is joined by fund founders Craig Gordon, MD, CEO and CIO at GordonMD® Global Investments LP and Srini Akkaraju, MD, PhD, Managing Partner at Samsara BioCapital,…

1
Episode: 23 - An Industry Veteran’s Insight on Data Governance and Provenance 16:49

12M ago16:49

16:49

In this episode of Evaluating Biopharma, host Ben Locwin and Scott Endicott, executive leader of Healthcare Solutions Integration, talk about data governance and data provenance—why they matter and how the industry can achieve them. With 30 years of experience, Endicott has a deep understanding of training AI and ML models, particularly when patien…

1
Episode: 22 - Insider’s Advice for Starting, Growing, Exiting a Biotech 35:01

1y ago35:01

35:01

In this month’s episode of Evaluating Biopharma, host Ben Locwin and Chris Major, founder and partner of BioProcess360 Partners, discuss the best ways to start a company to address technology gaps, why it is beneficial to collaborate with competitors (instead of going against each other), and the challenges encountered when planning to de-risk port…

1
Former Investor Who Chose Broadcasting Over Biotech ETFs 11:46

1y ago11:46

11:46

Former biotech investor, Brad Loncar has pivoted his career from investing to reporting on the industry. Instead of serving the biotech bubble, he hopes to reach a wide audience with interest in science. Loncar explains why he switched careers and sets out his ambitions for his channel, Biotech TV.RBC Capital Markets által

1
Biopharma EHS Podcast - Episode 29 Comparison of PDE Values (AI Generated) 11:57

1y ago11:57

11:57

This episode is a test use case where you can take a very technical scientific document and upload to a large language model to create a two-host podcast. The results were amazing.Dean Calhoun, CIH - Affygility Solutions által

1
Episode: 21 - How AI is Changing the Antibody R&D Game 31:35

1y ago31:35

31:35

In this month’s episode of Evaluating Biopharma, host Ben Locwin and Tony Arulanandam, SVP and head of R&D at Cytovia Therapeutics, discuss how AI is impacting the antibody R&D field, how companies are using AI to generate better sequences and improve efficacy, and methods on approaching regulators and tackling regulatory challenges. Arulanandam al…

1
Can AI Solve Molecule Mysteries that will Unlock Simpler Drug Discovery? 33:55

1y ago33:55

33:55

The hardest parts of drug discovery will be vastly simplified if the mysteries of molecules and proteins can be cracked. That may be beyond human capabilities – but AI is working hard on it. In this episode of RBC’s Pathfinders in Biopharma, Noël Brown is joined by Clarissa Desjardins, CEO of Congruence, and Laksh Aithani, CEO and Co-founder of Cha…

1
Shots-on-Goal Licensing Company Aims for Breakthroughs 13:52

1+ y ago13:52

13:52

A very special breed of animals is helping biotech and pharma companies in the quest for new human therapeutics. CFO Kurt Gustafson joins Pathfinders in Biopharma to explain the technologies behind OmniAb’s business model.RBC Capital Markets által

1
Episode: 20 - Optimal Talent Management in Biopharma with Mara Strandlund and Niamh Alix 19:38

1+ y ago19:38

19:38

In this month’s special episode of Evaluating Biopharma, host Ben Locwin interviews Mara Strandlund, chief people officer at National Resilience, and Niamh Alix, chief human resources officer at Prime Medicine, about the upcoming Talent in Biopharma Leadership workshop at the 2024 Bioprocessing Summit. Their conversation covers a wide variety of to…

1
Why Biopharma Needs to Tell Better Stories on Novel Drugs 15:31

1+ y ago15:31

15:31

Ronald Martell is a serial entrepreneur and biopharma veteran whose record includes the launch of Herceptin. He continues his mission to bring new drugs to patients with unmet medical needs. The CEO of Jasper Therapeutics explains his ambitions for his company’s new antibody therapy and for the future of the industry.…

1
Venture capital velocity: What’s driving renewed momentum in biotech? 35:03

1+ y ago35:03

35:03

In biotech, a recovery is already well underway. Expected interest rate cuts and improving valuations across public and private markets are creating a compelling environment for deals, entrances, exits, and trades to take shape. In this episode, biotech venture capital experts assess the sector’s sharper focus on funding fundamental science, evolvi…

1
Pharma Understands Phase One Data – But Does the Market? 25:30

1+ y ago25:30

25:30

Public biotech Pyxis Oncology is taking forward its innovative work on ADCs. President and CEO, Lara Sullivan, explains the company’s journey to find the right investors, and why she believes the markets still have some learning to do when analyzing data from early-stage studies.RBC Capital Markets által

1
Davern Capital sees GLP-1 Opportunities Beyond Obesity 9:39

1+ y ago9:39

9:39

Davern Capital’s founder, Elie Kobrin, approaches the biopharma market from a long/short perspective – but as a former doctor, he also speaks the language of medicine. He explains the fund’s approach and offers insights on hot topics in the current market.RBC Capital Markets által

1
Episode: 19 - The Critical Role of Starting Materials & Processes in Advanced Therapies 17:20

1+ y ago17:20

17:20

In this month’s episode of Evaluating Biopharma, host Ben Locwin and Joaquim Vives, head of production of advanced therapies at Banc de Sang i Teixits, discuss cell and gene therapies and what sets them apart from other therapeutics in terms of their processes. Vives also talks about the top characteristics of good starting materials and particular…

1
Betting on Healthcare’s Future Hits – and Misses 14:47

1+ y ago14:47

14:47

As a healthcare-focused, market-neutral investor, Vince Aita stays close to new product developments with a view to identifying future successes and failures. At RBC’s Global Healthcare Conference, he offered his insights on everything from the future of obesity innovation to the impact of the IRA.RBC Capital Markets által

1
Innovation and an Aging Population Drive MedTech 16:01

1+ y ago16:01

16:01

The MedTech sector continues to grow in the U.S. as innovation in patient treatments and delivery meets increased demand from an aging population. Medical technology analyst Shagun Singh assesses key data points from the RBC Capital Markets’ Doctor Days events, looking at how the healthcare sector can empower investors to position themselves for fu…

1
Biopharma Investors See Opportunities in Targeted Treatments and Gene Editing 20:39

1+ y ago20:39

20:39

Personalized, targeted drugs and gene therapies are still at the forefront of medical innovation, as we discovered at RBC Capital Markets annual Doctor Days meetings. These insightful forums bring together key opinion leader clinicians and researchers from various therapeutic fields with institutional investors to discuss where opportunities lie, t…

1
Biotech with a Mission to Target Unmet Cancer Needs 13:37

1+ y ago13:37

13:37

IDEAYA’s drug development programs center around addressing unmet patient needs. Its founder tells Pathfinders in Biopharma why he believes there has never been more opportunity for breakthroughs in the fight against cancer.RBC Capital Markets által

1
Episode: 18 - Bispecific Antibodies: What Are They? How Do They Work? An Expert's Thoughts 23:56

1+ y ago23:56

23:56

In this episode of Evaluating Biopharma, host Ben Locwin speaks with Dr. Stefan Schmidt, CEO of evitria AG, about bispecific antibodies. Dr. Schmidt goes into detail about current trends (from a CRO’s perspective) regarding the discovery and development phases of bispecific antibodies, why they are being made, and potential manufacturing issues. He…

1
The M&A Pool Set to Accelerate Biotech Innovation 13:51

1+ y ago13:51

13:51

Q1 2024 saw a handful of IPOs in the biotech sector, and mounting excitement over novel treatments. But there are less obvious trends in play, including a shift in focus by potential buyers in pharma. RBC’s biotech investment banking team analyzes deal activity in the year to date and what it signals for the sector’s future.…

1
How PIPEs finally unblocked biotech’s funding flows 17:36

1+ y ago17:36

17:36

The first quarter of 2024 has seen biotech’s funding drought broken, largely through private investment in public equity (PIPE) deals. In this episode of Pathfinders in Biopharma, three members of RBC’s biotech investment banking team look at the impact of PIPEs’ success on the sector and consider how long it can last – and why it has not been univ…

Podcastok, amelyeket érdemes meghallgatni

Biopharma Podcastok

Podcastok, amelyeket érdemes meghallgatni

Gyors referencia kézikönyv